ateganosine

Ateganosine is a first-in-class telomere-targeting small molecule anticancer agent developed by MAIA Biotechnology. Its mechanism involves inducing telomerase-dependent modification of telomeric DNA in cancer cells, leading to their death. Ateganosine also activates immune responses through both the innate cGAS/STING pathway and adaptive T-cell immunity. In preclinical studies and ongoing clinical trials, ateganosine has demonstrated potential for significant tumor regression and induction of cancer-specific immune memory when combined with PD-(L)1 inhibitors such as cemiplimab (Libtayo). It is being developed primarily for advanced non-small cell lung cancer (NSCLC) patients with telomerase-positive tumors who are resistant to standard checkpoint inhibitor therapies[8][10][6].

Other names

THIO6-thio-2'-deoxyguanosine